BenResearch_OR said:Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak.
This is where I part company with the consensus forming above. The affordability discussion here usually stops at individual tactics. At list price this class is out of reach for most of the people who would benefit, and no amount of appeal strategy changes that — it is a pricing problem wearing a paperwork costume.
The figures, for anyone assembling their own picture. For anyone assembling their own picture: Tmax is one to three days, terminal half-life about 165 to 170 hours, steady state at four to five weeks, and subcutaneous bioavailability near 89%. Those four numbers explain most of the questions people ask about timing.
Worth separating that from semaglutide, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.
TrialNerd_Beth said:The affordability discussion here usually stops at individual tactics.
Adding the part of the answer the thread has not reached. Steady state is the thing most people miss. The terminal half-life is about a week, so every dose step takes four to five weeks to fully express itself. Judging a step at day ten is judging the ascent, not the plateau, and it is the single commonest reason people escalate before they needed to.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsFollowing on from NauseaFreeNow — and this may be the naive question:
How much of the between-person variation is pharmacokinetic and how much is just adherence measured badly?
Reporting back.
Update: approved on the third attempt after a peer-to-peer. Nothing about my case changed; only who was doing the talking.